{"disease":{"id":"peritoneal-mesothelioma","name":"peritoneal mesothelioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01843374","title":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":571,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT07330271","title":"PTC-Guided Therapy for Peritoneal Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":347,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT05193006","title":"Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT05337735","title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05001880","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03054298","title":"CAR T Cells in Mesothelin Expressing Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT02399371","title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06057935","title":"A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04847063","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04462809","title":"Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02535312","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06543069","title":"Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03867578","title":"Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT01160458","title":"Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04088786","title":"Phase I Trial HIPEC With Nal-irinotecan","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Stony Brook University","has_results":false},{"nct_id":"NCT03608618","title":"Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"MaxCyte, Inc.","has_results":false},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT05449366","title":"Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04213794","title":"Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05041062","title":"A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Chicago","has_results":true}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}